ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1638

Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis

Katarina Kmetova1, Emily Chong2, NaveenKumar Somanathapura K3, Kavya Sugur2, Lyndsay Kluge2, Srilakshmi Yalavarthi3, Julia Ford3, Ora Singer4 and Yu Zuo3, 1Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI, 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann arbor, Ann arbor, MI, 3University of Michigan, Ann arbor, MI, 4University of Michigan, Huntington Woods, MI

Meeting: ACR Convergence 2024

Keywords: Biomarkers, giant cell arteritis, neutrophils, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Clinically isolated aortitis (CIA) is aortitis in patients without evidence of systemic disease, infection, or involvement of other vascular territories. CIA is discovered incidentally in up to 12 % of thoracic aortic aneurysm surgical repairs. Understanding of CIA’s pathogenesis remains limited, complicating diagnosis and management. Neutrophil extracellular traps (NET) have been implicated in escalating inflammation and vasculopathy in various diseases, including non-inflammatory aortic aneurysms. While elevated levels of circulating NET and impaired NET degradation have been observed in other large vessel vasculitides like giant cell arteritis (GCA) and Takayasu arteritis (TAK), the role of NET in CIA has not been studied. Our study aimed to evaluate multiple circulating NET markers in CIA patients and determine their potential role in promoting endothelial damage in aortitis.

Methods: Utilizing the MI-Aorta Aortitis Cohort, we identified 15 CIA patients diagnosed by aortic pathology or advanced imaging studies. Circulating NET markers and endothelial activation markers (ICAM-1, VCAM-1) were measured in plasma from patients with CIA, TAK (n=7), and GCA (n=11), as well as patients with thoracic aneurysms without aortitis (n=6). Additionally, we conducted ex vivo and in vitro experiments exposing human aortic endothelial cells (HAoEC) to CIA patient plasma or recombinant calprotectin to assess potential impacts on endothelial function.

Results: Among the circulating NET markers evaluated, calprotectin levels were elevated in both CIA and GCA plasma (Fig 1A). Increased levels of myeloperoxidase-DNA complexes were observed in all conditions (Fig 1B). Citrullinated histone H3 was uniquely elevated in GCA patients (Fig 1C). Additionally, CIA patients exhibited elevated levels of circulating ICAM-1 and VCAM-1 (p< 0.05, p< 0.001), whereas GCA patients only showed elevated VCAM-1 (p< 0.05). Calprotectin in CIA patients strongly correlated with CRP levels (r=0.889, p< 0.001). Mechanistically, high-calprotectin CIA plasma activated cultured HAoECs, leading to increased expression of surface adhesion molecules ICAM-1 and VCAM-1, crucial to inflammation and vasculopathy (Fig 2B-C). Furthermore, compared to CIA plasma with low calprotectin levels, CIA plasma with high calprotectin levels impaired the ability of HAoECs to produce nitric oxide (NO) under oxidative stress (Fig 3B), a capacity vital for maintaining vascular tone and mitigating inflammation following injury. Treating HAoECs with a high dose of recombinant calprotectin also compromised NO production under oxidative stress (Fig 3C).

Conclusion: Our study identifies calprotectin as a significant circulating NET marker elevated in CIA patients, where it correlates with other inflammatory indices. Mechanistically, calprotectin impairs endothelial integrity and reduces intracellular NO production. These findings suggest a mechanism by which calprotectin may contribute to endothelial dysfunction in CIA. In summary, calprotectin is a mechanism-informed biomarker that warrants further investigation in this challenging clinical scenario.

Supporting image 1

Figure 1: Circulating markers of neutrophil extracellular trap formation in patients with large vessel vasculitis or thoracic aortic aneurism.
Plasma samples were collected from 15 patients with clinically isolated aortitis, 7 with Takayasu arteritis, 11 with giant-cell arteritis, 6 with thoracic aneurysm without aortitis, and 34 healthy controls. Circulating levels of (A) calprotectin, (B) MPO-DNA complexes, and (C) citrullinated histone H3 were measured in patients’ plasma. Statistical analyses were performed using the Kruskal-Wallis test with multiple comparisons. * – p<0.05; ** - p<0.01; *** - p<0.001; MPO-DNA - myeloperoxidase-DNA complexes

Supporting image 2

Figure 2: Activation of human aortic endothelial cells (HAoEC) by CIA patients’ plasma.
(A) Schematic of a novel in-cell ELISA for HAoEC. HAoEC were cultured for 24h with 2.5% plasma from CIA patients with high or low calprotectin levels. Cells were then fixed, and surface expression of (B) ICAM_1 and (C) VCAM_1 was quantified as absorbance, using HRP coupled antibody. Results are presented as relative changes to unstimulated cells. Statistical analyses were performed using the Kruskal-Wallis test with multiple comparisons. * – p<0.05; ** - p<0.01

Supporting image 3

Figure 3: Effect of clinically isolated aortitis (CIA) patients’ plasma and recombinant calprotectin on HAoEC nitric oxide production under oxidative stress.
(A) Schematics of experiments. HAoECs were treated with 10% plasma from healthy controls and patients with high and low calprotectin for 24h. Cells were stained with DAF-FM Diacetate to analyze intracellular nitric oxide (NO) production via flow cytometry. Cells were challenged with hydrogen peroxide (H2O2) to assess their NO production capacity, and the ratio of NO produced after oxidative stress (H2O2) to baseline NO production was evaluated. (B) CIA plasma with high calprotectin levels impaired the HAoECs’ ability to produce NO in response to oxidative stress compared to plasma with low calprotectin levels. (C) Similarly, a high dose of recombinant calprotectin also impaired HAoECs’ NO production under oxidative stress. Statistical analyses were performed using the Kruskal-Wallis test with multiple comparisons. * – p<0.05; ** - p<0.01; ctrl – healthy control


Disclosures: K. Kmetova: None; E. Chong: None; N. Somanathapura K: None; K. Sugur: None; L. Kluge: None; S. Yalavarthi: None; J. Ford: None; O. Singer: None; Y. Zuo: None.

To cite this abstract in AMA style:

Kmetova K, Chong E, Somanathapura K N, Sugur K, Kluge L, Yalavarthi S, Ford J, Singer O, Zuo Y. Calprotectin, a Mechanistically Informed Biomarker for Clinically Isolated Aortitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/calprotectin-a-mechanistically-informed-biomarker-for-clinically-isolated-aortitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/calprotectin-a-mechanistically-informed-biomarker-for-clinically-isolated-aortitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology